Samsung Biologics Co.,Ltd. (KRX: 207940)
South Korea
· Delayed Price · Currency is KRW 949,000
+15,000 (1.61%)
Dec 30, 2024, 3:30 PM KST
Samsung Biologics Co.,Ltd. Revenue
Samsung Biologics Co.,Ltd. had revenue of 1.19T KRW in the quarter ending September 30, 2024, with 14.81% growth. This brings the company's revenue in the last twelve months to 4.36T, up 21.69% year-over-year. In the year 2023, Samsung Biologics Co.,Ltd. had annual revenue of 3.69T with 23.10% growth.
Revenue (ttm)
4,364.39B
Revenue Growth
+21.69%
P/S Ratio
15.33
Revenue / Employee
919.98M
Employees
4,744
Market Cap
66.90T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3,694.59B | 693.29B | 23.10% |
| Dec 31, 2022 | 3,001.30B | 1,433.29B | 91.41% |
| Dec 31, 2021 | 1,568.01B | 403.23B | 34.62% |
| Dec 31, 2020 | 1,164.78B | 463.19B | 66.02% |
| Dec 31, 2019 | 701.59B | 165.79B | 30.94% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celltrion | 2,876.25B |
| Yuhan | 2,008.84B |
| SK Biopharmaceuticals | 511.33B |
| SK bioscience Co.,Ltd. | 201.30B |
| Hanmi Pharm. | 1,566.25B |
| Hanmi Science | 1,283.65B |
| GC Biopharma | 1,643.98B |
| Hanall Biopharma | 134.24B |